Field Sales Rare Disease - Inborn Errors of Metabolism
About the job
- A bachelor's degree is required.
- Eight years of experience, including at least five years in healthcare or biotech and three years of field-based experience in account management, sales, and/or field reimbursement.
- A documented track record of field sales success is required.
- Strategic business acumen and cross-functional collaborative leadership with internal stakeholders, including marketing, medical, clinical operations, and patient services, are required.
- Demonstrated experience effectively presenting clinical or scientific information is required.
- Must live in the territory, which includes Illinois, Kansas, and Missouri; the territory may change based on business needs.
- Approximately 50–60% travel, dependent on geography, is required; overnight travel is required as needed.
- Serve as the territory business owner, focusing on impact and territory analysis, patient diagnosis and care through healthcare professional education, educating healthcare professionals about approved products, and assisting with treatment fulfillment.
- Develop and nurture effective business relationships with key stakeholders, including healthcare professionals, registered dieticians, genetic counselors, pharmacists, and related support staff.
- Build effective working relationships with internal and external stakeholders, drive agreement and decisions among multiple stakeholders, understand stakeholder perspectives, adapt communication style to different needs and audiences, and drive alignment toward work goals.
- Develop and maintain a strategic territory business plan focused on key academic centers, community targets within priority specialties, territory opportunities, and challenges.
- Determine and implement a suitable daily and weekly travel schedule and call plan to provide effective coverage for key accounts.
- Execute programs, high-impact in-services, and other educational opportunities in the territory.
- Complete compliance training, internal product and disease-state training, Veeva administration, monthly expense reports, and other administrative expectations.
- Rare disease experience is preferred.
- Experience successfully launching biopharma or pharmaceutical products is preferred.
About the company
Ultragenyx Pharmaceutical develops and commercializes therapies for rare and ultra-rare genetic diseases. It advances a diversified pipeline and brings FDA-approved drugs, like burosumab for Tumor Induced Osteomalacia and UX007 for Long-chain Fatty Acid Oxidation Disorders, to market while ensuring continuous supply for patients. The company differentiates itself through a broad portfolio focused on high-need, niche conditions and a strong emphasis on uninterrupted patient access. Its goal is to turn scientific research into accessible treatments and lead the rare-disease market.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Novato, California
Founded
2010
Get referred to Ultragenyx Pharmaceutical
See people who can refer or advise you
Simplify's Take
What believers are saying
- FDA approved FAYUVI on September 17, 2026, Ultragenyx's second gene-therapy approval.
- FDA approved GENGLYCOS on August 19, 2026, adding a first-in-class GSDIa launch.
- Q2 2026 revenue reached $214 million, and management reaffirmed 2027 profitability targeting lower spending.
What critics are saying
- Pomerantz opened a securities investigation on September 24, 2026 after GTX-102's collapse.
- GTX-102 missed both Phase 3 Aspire endpoints on September 2, 2026, crushing confidence.
- GENGLYCOS faces accelerated-approval confirmatory obligations; failure removes approval, revenue, and credibility by 2028.
What makes Ultragenyx Pharmaceutical unique
- Ultragenyx owns an unusually deep rare-disease launch engine: Crysvita, Dojolvi, Evkeeza, Mepsevii.
- Bedford, Massachusetts manufacturing supports GENGLYCOS and FAYUVI commercialization, reducing external supply dependence.
- Ultragenyx spans metabolic and neurogenetic diseases, giving it multiple shots within one niche.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Paid Vacation
Volunteer Days
Stock Options
Company Equity
Wellness Program
Professional Development Budget
Tuition Reimbursement
Growth & Insights and Company News
6 month growth
↓ -3%1 year growth
↓ -1%2 year growth
↓ -1%INVESTOR ALERT: Pomerantz law Firm investigates claims on behalf of investors of Ultragenyx Pharmaceutical Inc. - RARE. Sep 24, 2026, 17:34 ET NEW YORK, Sept. 24, 2026 /PRNewswire/ - Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Ultragenyx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On September 2, 2026, Ultragenyx issued a press release "announc[ing] results from the Phase 3 Aspire study for apazunersen (GTX-102) in Angelman syndrome." Per the press release, "[t]he study did not achieve the primary endpoint of change from Baseline in Bayley-4 cognitive raw score nor the key secondary endpoint of net response in Multidomain Responder Index (MDRI)." On this news, Ultragenyx's stock price fell $11.68 per share, or 44.03%, to close at $14.85 per share on September 3, 2026. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. SOURCE Pomerantz LLP
Ultragenyx Pharmaceutical received FDA approval on 17 September for Fayuvi, the first treatment for neurologic manifestations of Sanfilippo syndrome Type A in paediatric patients. The stock jumped over 12% on the news but remains down nearly 40% for the year. The approval strengthens Ultragenyx's 2027 profitability target. The company posted a $575 million loss on $673 million revenue in 2025 and projects $730 million to $760 million in 2026 revenue from current products, excluding new launches. Fayuvi carries a $3.95 million list price for one-time treatment. JP Morgan estimates peak global sales of $200 million to $250 million, representing roughly 26% of Ultragenyx's 2026 revenue guidance at the lower end. The drug will become available to patients within 30 to 60 days. Hedge fund holdings fell to 50 in Q2 from 55 in Q1, though AQR Capital Management increased its stake 44% to 6.6 million shares.
The US Food and Drug Administration has approved Ultragenyx's Fayuvi gene therapy for paediatric patients with Sanfilippo syndrome Type A, a rare inherited condition that progressively damages the brain and nervous system. The company has priced the one-time treatment at $3.95 million. The disease causes children to gradually lose cognitive, speech and motor skills due to toxic accumulation of complex sugars in the body and brain. Administered as a single intravenous infusion, Fayuvi delivers a functional gene copy enabling the body to produce the missing enzyme. Ultragenyx said lifetime care costs for affected children can exceed $8 million. J.P. Morgan analysts estimate the therapy could reach peak worldwide sales of $200 million to $250 million. The treatment will be available at specialised US centres within 30 to 60 days.
Ultragenyx Pharmaceutical has received FDA approval for FAYUVI, the first-ever treatment for Sanfilippo syndrome Type A, a progressive and fatal neurodegenerative disease. The gene therapy, also known as UX111, is approved for pediatric patients with the condition. FAYUVI represents Ultragenyx's second gene therapy approval and sixth FDA approval overall. The company received a Priority Review Voucher with the approval. The commercial product is expected to be available to ship to Qualified Treatment Centers within 30 to 60 days. Ultragenyx's UltraCare programme will support access to the treatment. The approval follows decades of research, advocacy and collaboration across the Sanfilippo community, patient organisations and industry partners. The company aims to bring the treatment to patients globally.
Ultragenyx plunges after-hours from rare disease drug trial failure. Angelman syndrome is a rare genetic nervous system disorder causing severe developmental delay 2 hours ago Drug trial setbacks can still hit a company's shares hard, even after recent good news. Investors often react strongly when a late-stage study disappoints. Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) (FRA: UP0) saw its stock fall more than 40 per cent in after-hours trading after it reported unfavourable results from its Phase 3 Aspire study of apazunersen for Angelman syndrome. The medicine is designed to help restore a missing protein in the brain. Doctors give it by injection into the spinal fluid. In the trial, children who received the drug showed no clear improvement in thinking skills compared with those in the control group. They also failed to show benefits on a wider set of daily abilities. The groups looked much the same. JPMorgan Chase & Co (NYSE: JPM) slashed its price target from US$80 to US$36 as a result. Baird also cut its target from US$40 to US$16 while Evercore ISI reduced its expectation from US$34 to US$16. Ultragenyx says it plans to review the program and implement significant expense cuts. Angelman syndrome is a rare genetic condition that begins in early childhood. It occurs when a gene from the mother does not work properly. Children typically have delayed development, little or no speech, balance and movement problems, and seizures. Strikingly, many display a happy and excitable nature, with frequent smiling and laughter that stands out against the other challenges. The condition lasts a lifetime and requires ongoing care. No approved treatments can fix the root cause. Recent approval offers lingering optimism. This setback follows a major success. The US Food and Drug Administration recently granted accelerated approval to Ultragenyx's gene therapy GENGLYCOS for people aged eight and older with glycogen storage disease type Ia. Patients with this rare condition must take large amounts of cornstarch throughout the day and night to keep blood sugar stable. A newly published 96-week study showed that those treated with the gene therapy cut their daily cornstarch use by an average of 61 per cent while keeping sugar levels safe. Many reduced or stopped nighttime doses. Ultragenyx's leading competitors are Biomarin Pharmaceutical Inc (NASDAQ: BMRN) (FRA: BM8) and Sarepta Therapeutics Inc (NASDAQ: SRPT) (FRA: AB3A). They are rivals because they all specialise in rare genetic diseases and compete in the same overall biotech space for investors, talent and attention - not because they sell drugs for the same conditions.